ESSA Pharma Inc. — Director's Dealing 2025

Aug 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2025-08-05

Reporting Person: BVF PARTNERS L P/IL (10% Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND L P (10% Owner)
Reporting Person: BVF I GP LLC (10% Owner)
Reporting Person: BIOTECHNOLOGY VALUE FUND II LP (See Explanation of Responses)
Reporting Person: BVF II GP LLC (See Explanation of Responses)
Reporting Person: Biotechnology Value Trading Fund OS LP (See Explanation of Responses)
Reporting Person: BVF Partners OS Ltd. (See Explanation of Responses)
Reporting Person: BVF GP HOLDINGS LLC (10% Owner)
Reporting Person: BVF INC/IL (10% Owner)
Reporting Person: LAMPERT MARK N (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-05	Common Stock	X	1481634	$0.0001	Acquired	6194224	Direct
2025-08-05	Common Stock	X	1235030	$0.0001	Acquired	4726809	Direct
2025-08-05	Common Stock	X	203336	$0.0001	Acquired	560808	Direct
2025-08-05	Common Stock	S	79	$1.8779	Disposed	6194145	Direct
2025-08-05	Common Stock	S	66	$1.8779	Disposed	4726743	Direct
2025-08-05	Common Stock	S	11	$1.8779	Disposed	560797	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-05	Pre-funded Warrants	$0.0001	X	1481634	Disposed		Common Stock (1481634)	Direct
2025-08-05	Pre-funded Warrants	$0.0001	X	1235030	Disposed		Common Stock (1235030)	Direct
2025-08-05	Pre-funded Warrants	$0.0001	X	203336	Disposed		Common Stock (203336)	Direct

Footnotes

F1: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

F3: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

F4: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

F5: On August 5, 2025, the Reporting Persons exercised the pre-funded warrants to purchase 2,920,000 shares of the Issuer's common stock for $0.0001 per share.The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 156 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 2,919,844 shares.